A phase 4 study comparing Sanofi's protein-based Nuvaxovid vaccine with Moderna's mRNA-based mNEXSPIKE found Nuvaxovid caused significantly fewer and less severe side effects. Conducted with 1,000 US adults, the study showed Nuvaxovid recipients experienced over 50% fewer severe systemic symptoms and 75% fewer severe local reactions. These findings may improve vaccine acceptance and routine COVID-19 vaccination uptake, addressing ongoing health risks despite the pandemic's end. Sanofi plans to expand Nuvaxovid availability in multiple markets from 2026 onward.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Paulo Fontoura has resigned from the Board of Directors at Lakefront Biotherapeutics following his appointment as Executive Vice President and Global Head of Research & Development Pharma at Sanofi. Lakefront's board chair congratulated Fontoura and ...
